Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07054944 · ClinicalTrials.gov registry record
Tumor-Lymph Node Mapping
A clinical trial, sponsored by University of Rochester.
- Recruiting
- Registry status
- 10
- Enrollment target
NCT07054944: Recruiting study, sponsored by University of Rochester.
NCT07054944 is a clinical trial that is actively recruiting participants, run by University of Rochester. The registered enrollment target is 10 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07054944 is actively recruiting participants, sponsored by University of Rochester.
- RECRUITING
- Registry status
- 10 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the feasibility and safety of ICG-guided intraoperative lymphography for detecting sentinel lymph nodes (SLN) in pediatric patients with solid tumors who require retroperitoneal lymph node dissection/sampling. This trial is a single-site cross-sectional study. The injection of ICG directly into lymphatics draining the primary tumor will take place at the time of operation after the patient is under anesthesia.
Primary Outcome
Success is defined as the intraoperative identification of at least one fluorescent sentinel lymph node (SLN) after indocyanine green (ICG) injection using an Iridium system optimized for near-infrared detection. Visualization of the SLN indicates uptake of ICG within the lymphatic basin.
Interventions
- DIAGNOSTIC_TEST ICG (Indocyanine Green)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2026-04-13 |
| Est. Completion | 2028-07-30 |
What NCT07054944 shows while recruiting
NCT07054944 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 10 participants, a relatively small participant target.
The record links to 0 conditions, and to 1 intervention - of which ICG (Indocyanine Green) is the first listed.
NCT07054944 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07054944 about?
NCT07054944 is a clinical study titled "Tumor-Lymph Node Mapping". The purpose of this study is to assess the feasibility and safety of ICG-guided intraoperative lymphography for detecting sentinel lymph nodes (SLN) in pediatric patients with solid tumors who require retroperitoneal lymph node dissection/sampling. This trial is a single-site cross-sectional study....
What is the current status of trial NCT07054944?
This trial is currently recruiting. The enrollment target is 10 participants. The study started on 2026-04-13. Estimated completion is 2028-07-30.
What interventions are being tested in trial NCT07054944?
The interventions under investigation include: ICG (Indocyanine Green) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07054944?
This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI